Germany’s Merck (MRK: DE) on Wednesday announced two appointments to head its businesses in North America and China in a bid to strengthen its position in the regions.
The comopany named Gary Zieziula president and managing director for its business in North America, and Marc Horn to take the helm of the biopharma business in China.
Mr Zieziula will be responsible for the company’s business in the USA and Canada, with immediate effect. Mr Zieziula joined Merck in 2014 as chief commercial officer in the USA. He succeeds Paris Panayiotopoulos, who accepted a new position outside of Merck at the end of last year.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze